Home
Solutions
Resources
About
Contact
Book a Demo
Home
Solutions
Overview
AIxURO
AIxTHY
coming soon
AIxPAP
coming soon
AIxPUL
coming soon
Resources
About
Contact
Contact us
AI-Driven
Digital Cytology:
Cancer Cells Have Nowhere to Hide
Quantitative and qualitative data from our AI-powered computational platform enhances cytology insights to improve workflows and quality of patient care in the battle against cancer.
Schedule Your Personalized Demo
Data-Driven Pathology to Benefit All Stakeholders
AIxMed’s digital cytology solutions are as much about enhancing workflow efficiencies as they are about improving patient care and outcomes when battling cancer.
Pathologists
  • Whole slide imaging
  • More slides, less time, fewer reviewers
  • Reduce bottlenecks and turnaround times
  • Reallocate labor
  • Confidence in results
Providers
  • Confidence in diagnosis, monitoring, and treatment
  • Potential to catch and treat earlier-stage cancers
  • High-quality patient care
Patients
  • Comfortable sample collection
  • Supports personalized patient care
  • Catch and treat earlier-stage cancers
Payors
  • Cost-effective
  • High-quality patient care
Integrate the AI-powered computational platform from AIxMed to enhance and ease your current cytology workflow
Manual
Qualitative
Slide
Microscope + Pathologist
Initial analysis and cell marking
Pathologist
Final Dx Report
AI-Powered
Quantitative
Qualitative
Slide
Relevant cell characterization
Pathologist
Report in secure cloud
AlxMed
AlxMed
IMPACT
Manual
Automatically identifies suspicious and atypical cells in digital images
FASTER
PATIENT
CARE
Manual screening of entire cell area to locate abnormal cells in challenging preps
Automation for speed and consistency
Human delays compounded by logistics and workload
Digital marking and records storage of abnormal cells directly into electronic health record (EHR)
Manual marking of abnormal cells or the glass slide with subsequent physical filing
Rapid consultations with whole slide images and software
Physical limitations and delays based on location of pathologist
Quick assessment of digital images showcasing suspicious and abnormal cells
Manual microscopic review of screened and marked glass slide
Consistent quantitative and qualitative data

PATIENT
CARE
Variable findings based on user experience & qualitative only assessments
Adhere to The Paris System (TPS) standards
Individual interpretation of The Paris System
Instant scalability with current personnel
CHEAPER
Volume fluctuations require additional cytologists
Are You Ready to Join the Revolution?
AIxMed’s AI-powered computational platform combines advanced machine learning with computer vision to discover deep insights in cytology samples.
Book A Demo Now
Our Digital Cytology Platform Targets Devastating Cancers
Advanced digital cytology can transform laboratory workflows, enhance quality of care, and reduce expenses.
For Urine Cytology: Bladder Cancer
Find out more
AIxURO accurately identifies suspicious and atypical cells using a non-invasive urine sample.
View more
4TH
Most common cancer in men
16.8K
Estimated U.S. deaths
83.2K
Estimated new U.S cases
77%
High-grade 10-year recurrence rate
$9.4B
Estimated national expenditure for bladder cancer care
For Thyroid Cytology: Thyroid Cancer
Coming soon
AIxTHY: Revolutionizing thyroid cancer detection and diagnosis.
Coming soon
5TH
Most common cancer in U.S. women
2.2K
Estimated U.S. deaths per year
53K
Estimated new U.S. cases
25%
Of fine needle aspiration cytology (FNAC) tests inconclusive
$6.1B
Estimated U.S. expenditure for thyroid cancer care
For Cervical Cytology: Cervical Cancer
Coming soon
AIxPAP: Cervical cancer is preventable but remains a major health challenge.
Coming soon
4TH
Most common cancer in women worldwide
~350K
Estimated global deaths per year
~660K
Estimated new global cases
70%
WHO target of women who should be screened
$2.3B
Estimated U.S. expenditure for cervical cancer care
For Pulmonary Cytology: Lung Cancer
Coming soon
AIxPUL: Empowering precision in lung cancer detection.
Coming soon
3RD
Most common cancer in men and women
135K
Estimated U.S. deaths
234K
Estimated new U.S. cases
27%
5-Year survival rate U.S.
$23.8B
Estimated national expenditure for lung cancer care
Samuel Chen
Chief Executive Officer, President & Co-Founder
Bringing over 25 years of software development experience to the team, Samuel Chen is the president and CEO of AIxMed. He was the Vice President of Software Development at Trend Micro and helped establish the company as one of the top three information security companies in the world and Taiwan’s #1 software company. Additionally, Mr. Chen held executive leadership roles at ASUSTek and Compal and founded the Compal AI Lab. Mr. Chen graduated from National Chiao-Tung University and attained a Master’s of Science degree in computer science from the University of Southern California.
Tien-Jen Liu, M.D.
Chief Operating Officer & Co-Founder
Tien-Jen Liu, MD, is an experienced attending physician with a proven history in the biotechnology industry. Dr. Liu is skilled in clinical research, medical device development, clinical study, and business development. He is also the director of the biomedical innovation program at a medical university.
Stephen Hess
SVP Business Development
Steph Hess is an experienced business development professional bringing two decades of IVD and life science experience to the team in both Product and Business Development. He has consulted for dozens of start-up companies and helped introduce multiple products to the market. Mr. Hess was previously VP Global Business Development at Invetech and VP Global Sales and Marketing at IDEX Health and Science. Steph obtained an Engineering Degree from Rutgers University and a Master’s of Science degree in Management from WPI.
Barbara Crothers, D.O.
Chief Scientist
Dr. Crothers is an internationally-recognized cytopathologist and co-editor of The International System for Reporting Serous Cytopathology with over 30 years of active- duty military experience as a leader in pathology and cytopathology. Prior to joining AIxMED, she was a senior consultant pathologist at the Joint Pathology Center, the premier reference center for the Department of Defense and Veteran’s Administration. She is board-certified in Anatomic & Clinical Pathology and Cytopathology. She has served as the President, American Society of Cytopathology (ASC); Pathology Consultant to the Army Surgeon General; Chair of the College of American Pathologist’s (CAP) Cytopathology Committee; Pathology Program Director; Chief, Department of Pathology; and Cytopathology Medical Director. She has received numerous professional, military and academic honors and awards, most recently the ASC’s Papanicolaou Award for lifetime achievement.
Join Our Newsletter
Join the revolution
Subscribe to our newsletter to receive the latest updates from AlxMed.
Copyright © 2019-2025 AIxMed, Inc.
For Research Use Only. Not for use in diagnostic procedures.
Privacy Policy
•
Terms  & Conditions
•
Legal Info
For Research Use Only. Not for use in diagnostic procedures.